Drugs Index
Medical Conditions:
- Medical Conditions G
- Medical Conditions I
- Medical Conditions P
- Medical Conditions C
- Medical Conditions N
- Medical Conditions T
- Medical Conditions E
- Medical Conditions D
- Medical Conditions F
- Medical Conditions H
- Medical Conditions M
- Medical Conditions B
- Medical Conditions U
- Medical Conditions O
- Medical Conditions S
- Medical Conditions A
- Medical Conditions R
- Medical Conditions L
- Medical Conditions W
- Medical Conditions V
- Medical Conditions K
- Medical Conditions J
- Medical Conditions X
Drug Classes
- Drug Classes A
- Drug Classes M
- Drug Classes H
- Drug Classes C
- Drug Classes B
- Drug Classes U
- Drug Classes T
- Drug Classes O
- Drug Classes I
- Drug Classes N
- Drug Classes V
- Drug Classes E
- Drug Classes G
- Drug Classes P
- Drug Classes L
- Drug Classes Q
- Drug Classes F
- Drug Classes S
- Drug Classes D
- Drug Classes R
- Drug Classes 5
- Drug Classes K
Drugs Information:
Drugs List
1. Name Of The Medicinal Product
Lanacort Creme.
2. Qualitative And Quantitative Composition
|
Active Ingredient: |
% w/w |
Specification |
|
Hydrocortisone acetate |
1.0 |
BP. |
3. Pharmaceutical Form
Cream.
4. Clinical Particulars
4.1 Therapeutic Indications
Uses: Irritant dermatitis, contact allergic dermatitis, insect bite reactions and eczema (mild to moderate).
4.2 Posology And Method Of Administration
For topical application to the skin.
Adults, children over 10 and the elderly:
Apply sparingly over a small area once/twice a day for a maximum of one week. If the condition does not improve, consult your doctor.
Do not use for children under 10 without medical advice.
4.3 Contraindications
The product should not be used on the eyes or face, the ano-genital areas or on broken or infected skin including cold sores, acne and athletes' foot.
4.4 Special Warnings And Precautions For Use
The product labelling will include the following statements:
Contains hydrocortisone. If the condition does not improve, consult
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or your pharmacist.
- This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.
In this leaflet:
- 1. What your medicine is and what it is used for
- 2. Before you receive it
- 3. How it is administered
- 4. Possible side effects
- 5. Storing it
Lidocaine Injection with Preservative 1%
The active ingredient in this medicine is lidocaine hydrochloride. This is the new name for lignocaine hydrochloride. The ingredient itself has not changed.
This injection contains the active ingredient lidocaine hydrochloride 1%. Each ml contains 10 mg of lidocaine hydrochloride.
This injection also contains the following inactive ingredients:
Sodium chloride, methylhydroxybenzoate (E218), propylhydroxybenzoate (E216) and water for injections.
Holder of the Marketing Authorisation:
Lidocaine Hydrochloride BP
Laryngojet 4%W/V
Please read this leaflet. It contains important information about your medicine. If you have any questions, please ask your doctor or nurse.
What is this medicine?
This medicine is called Lidocaine Hydrochloride BP Laryngojet 4% w/v. It is a sterile solution which comes in a glass vial and contains 160mg lidocaine hydrochloride in 4ml as the active ingredient. It also contains sodium hydroxide and water.
The active ingredient in this medicine is Lidocaine hydrochloride. This is the new name for Lidocaine (Lignocaine) hydrochloride. The ingredient itself has not changed.
There is one 4ml vial in each carton.
It is a local anaesthetic. It numbs the area it is applied to.
Who makes it?
Marketing Authorisation Holder:
Manufacturer:
Losec Capsules 10 mg, 20 mg and 40 mg
omeprazole
Please read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
- 1. What Losec Capsules are and what they are used for
- 2. Before you take Losec Capsules
- 3. How to take Losec Capsules
- 4. Possible side effects
- 5. How to store Losec Capsules
- 6. Further information
What Losec Capsules are and what they are used for
Losec Capsules contain a medicine called omeprazole. This belongs to a group of medicines called ‘proton pump inhibitors’. They work by reducing the amount of acid that your stomach produces.
Losec Capsules are used to treat the following conditions:
- ‘Gastro-oesophageal reflux disease’ (GORD).
- Acid indigestion which can cause stomach pain or discomfort (dyspepsia).
- Ulcers that are infected with bacteria called ‘Helicobacter pylori’. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.
1. Name Of The Medicinal Product
Lescol XL 80 mg prolonged-release tablets.
Nandovar XL 80mg prolonged release tablets.
2. Qualitative And Quantitative Composition
Active substance: fluvastatin (as fluvastatin sodium)
Lescol XL 80 mg prolonged-release tablets:
One prolonged-release tablet of Lescol XL contains 84.24 mg fluvastatin sodium equivalent to 80 mg fluvastatin free acid.
For a full list of excipients, see Section 6.1.
3. Pharmaceutical Form
Prolonged-release tablet.
Lescol XL 80 mg prolonged-release tablets:
Yellow, round, slightly biconvex film-coated tablets with beveled edges, approx. 10 mm in diameter, debossed with “LE” on one side and “NVR” on the other side.
4. Clinical Particulars
4.1 Therapeutic Indications
Dyslipidaemia
Treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
Secondary prevention in coronary heart disease
Secondary prevention of major adverse cardiac events in adults with coronary heart disease after percutaneous coronary interventions (see section 5.1).
4.2 Posology And Method Of Administration
Adults
Dyslipidaemia
Prior to initiating treatment with Lescol XL, patients should be placed on a standard cholesterol-lowering diet, which should be continue
Losec MUPS Tablets 10 mg, 20 mg and 40 mg
omeprazole
Please read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
- 1. What Losec MUPS Tablets are and what they are used for
- 2. Before you take Losec MUPS Tablets
- 3. How to take Losec MUPS Tablets
- 4. Possible side effects
- 5. How to store Losec MUPS Tablets
- 6. Further information
What Losec MUPS Tablets are and what they are used for
Losec MUPS Tablets contain a medicine called omeprazole. This belongs to a group of medicines called ‘proton pump inhibitors’. They work by reducing the amount of acid that your stomach produces.
Losec MUPS Tablets are used to treat the following conditions:
- ‘Gastro-oesophageal reflux disease’ (GORD).
- Acid indigestion which can cause stomach pain or discomfort (dyspepsia).
- Ulcers that are infected with bacteria called ‘Helicobacter pylori’. If you have this condition, your doctor may also prescribe antibiotics to treat th
1. Name Of The Medicinal Product
Leukeran® Tablets 2 mg
2. Qualitative And Quantitative Composition
Each tablet contains 2 mg of the active ingredient chlorambucil.
3. Pharmaceutical Form
Film-coated tablet
4. Clinical Particulars
4.1 Therapeutic Indications
Leukeran is indicated in the treatment of Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinaemia.
4.2 Posology And Method Of Administration
Adults: Hodgkin's Disease: Used as a single agent in the palliative treatment of advanced disease a typical dosage is 0.2 mg/kg/day for 4-8 weeks. Leukeran is usually included in combination therapy and a number of regimes have been used. Leukeran has been used as an alternative to nitrogen mustard with a reduction in toxicity but similar therapeutic results.
Non-Hodgkin's Lymphoma: Used as a single agent the usual dosage is 0.1-0.2 mg/kg/day for 4-8 weeks initially, maintenance therapy is then given either by a reduced daily dosage or intermittent courses of treatment. Leukeran is useful in the management of patients with advanced diffuse lymphocytic lymphoma and those who have relapsed after radiotherapy. There is no significant difference in the overall response rate obtained with chlorambucil as a single agent and combination chemotherapy in patients with advanced non-Hodgkin's lymphocytic lymphoma.
Chronic Lymphocytic Leukaemia: Treatment with Leukeran is usually started after the patient has developed symptoms or when there is evidence of impair
1. Name Of The Medicinal Product
Lamotrigine 100 mg dispersible/ chewable tablets
2. Qualitative And Quantitative Composition
Each Lamotrigine 100 mg dispersible/ chewable tablet contains 100 mg lamotrigine.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Dispersible/ chewable tablet
White to off-white, rounded square shaped uncoated tablets debossed with 'H' on multifaceted side and '78' on flat side.
4. Clinical Particulars
4.1 Therapeutic Indications
Epilepsy:
Adults and adolescents aged 13 years and above
• Adjunctive or monotherapy treatment of partial seizures and generalised seizures, including tonic-clonic seizures.
• Seizures associated with Lennox-Gastaut syndrome. Lamotrigine is given as adjunctive therapy but may be the initial antiepileptic drug (AED) to start with in Lennox-Gastaut syndrome.
Children and adolescents aged 2 to 12 years
• Adjunctive treatment of partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut syndrome.
• Monotherapy of typical absence seizures.
Bipolar disorder:
Adults aged 18 years and above
• Prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes (see section 5.1).
Lamotrigine is not indicated for the acute treatment of manic or depressive episodes.
4.2 Posology And Method Of Administration
LOPRESOR Tablets 50 and 100 mg
(metoprolol tartrate)
What you need to know about Lopresor Tablets
Your doctor has decided that you need this medicine to help treat your condition.
Please read this leaflet carefully before you start to take your medicine. It contains important information. Keep the leaflet in a safe place because you may want to read it again.
If you have any other questions, or if there is something you don’t understand, please ask your doctor or pharmacist.
This medicine has been prescribed for you. Never give it to someone else. It may not be the right medicine for them even if their symptoms seem to be the same as yours.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
- 1. What Lopresor Tablets are and what they are used for
- 2. Things to consider before you start to take Lopresor Tablets
- 3. How to take Lopresor Tablets
- 4. Possible side effects
- 5. How to store Lopresor Tablets
- 6. Further information
What Lopresor Tablets are and what they are used for
Metoprolol tartrate, the active ingredient in Lopresor Tablets, is one of a group of medicines called beta-blockers. Beta-blockers slow the heart beat, lessen the force with which the heart muscle contracts and reduce blood vessel contraction in the heart, brain, and throughout the body.
- Lopresor Tablets are used to treat a number of different conditions including:
High blood pressure
Angina (chest pain)
Some heart disorders, for example, heart attack or irregular heart beats.
1. Name Of The Medicinal Product
Lopresor Tablets 100mg
2. Qualitative And Quantitative Composition
Each tablet contains 100mg metoprolol tartrate BP
3. Pharmaceutical Form
Film coated tablet
4. Clinical Particulars
4.1 Therapeutic Indications
Hypertension and angina pectoris, cardiac arrhythmias, especially supraventricular tachyarrhythmias. Adjunct to treatment of thyrotoxicosis. Early intervention ith Lopresor in myocardial infarction reduces infarct size and the incidence of ventricular fibrillation. Pain relief may also decrease the need for opiate analgesics. Lopresor has been shown to reduce mortality when administered to patients with acute myocardial infarction. Prophylaxis of migraine.
4.2 Posology And Method Of Administration
Lopresor tablets should be administered orally and swallowed unchewed. The dose must always be adjusted to the individual requirements of the patient but should not exceed 400mg/day. The following are guidelines:
Adults
Hypertension: initially a dose of 100mg per day should be prescribed either as single or divided doses. Depending upon the response the dosage may be increased by 100mg per day at weekly intervals to 200mg daily given in single or divided doses. Over the dosage range most patients may be expected to respond rapidly and satisfactorily. A further reduction in blood pressure may be achieved if Lopresor is used in conjunction with an antihypertensive diuretic or other hypotensive agent.
Lopresor may be administered with benefit both to previously untreated patients with hypertension and to those in whom the response to previous therapy is inadequate. In the latter type of patient the previous therapy may be cont
1. Name Of The Medicinal Product
Levonelle® 1500 microgram tablet
2. Qualitative And Quantitative Composition
The tablet contains 1500 microgram of levonorgestrel
For excipients see section 6.1
3. Pharmaceutical Form
Tablet
The tablet is round and white with an impressed mark of "G00" on one side.
4. Clinical Particulars
4.1 Therapeutic Indications
Emergency contraception within 72 hours of unprotected sexual intercourse or failure of a contraceptive method.
4.2 Posology And Method Of Administration
For oral administration: One tablet should be taken as soon as possible, preferably within 12 hours, and no later than 72 hours after unprotected intercourse (see section 5.1).
If vomiting occurs within three hours of taking the tablet, another tablet should be taken immediately.
Levonelle 1500 can be used at any time during the menstrual cycle unless menstrual bleeding is overdue.
After using emergency contraception it is recommended to use a barrier method (e.g. condom, diaphragm or cap) until the next menstrual period starts. The use of Levonelle 1500 does not contraindicate the continuation of regular hormonal contraception.
Children: Levonelle 1500 is not recommended in children.
Very limited data are available in women under 16 years of age.
4.3 Contraindications
Hypersensitivity to the active substance levonorgestrel or any of the excipients.
4.4 Special Warnings And Precautions For Use
|
Emergency contraception is an occasional method. It should in no instance |
LIQUIFILM TEARS
1.4% w/v, eye drops, solution
Polyvinyl alcohol
Read all of this leaflet carefully because it contains important information for you.
This medicine is available without prescription. However, you still need to use LIQUIFILM TEARS carefully to get the best results from it.
- Keep this leaflet. You may need to read it again.
- Ask your pharmacist if you need more information or advice.
- You must contact a doctor if your symptoms worsen or do not improve after 3 days.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
- 1. What LIQUIFILM TEARS is and what it is used for
- 2. Before you use LIQUIFILM TEARS
- 3. How to use LIQUIFILM TEARS
- 4. Possible side effects
- 5. How to store LIQUIFILM TEARS
- 6. Further information
What Liquifilm Tears Is And What It Is Used For
LIQUIFILM TEARS is a substitute for tears and contains a lubricant called polyvinyl alcohol. It is an eye drops solution used for the relief of the symptoms of dry eye (such as soreness, burning, irritation or dryness) caused by your eyes not producing enough tears.
Before You Use Liquifilm Tears
Do NOT use LIQUIFILM TEARS:
- if you are allergic (h
1. Name Of The Medicinal Product
Lemsip Cough Dry
2. Qualitative And Quantitative Composition
|
Active ingredients |
Quantity/dose |
Specification |
|
Glycerol |
0.25 ml |
EP |
|
Honey |
500.00 mg |
HSE |
|
Citric acid monohydrate |
25.00 mg |
EP |
|
Lemon oil terpeneless |
0.0005 ml |
BP |
|
Syrup |
3.75 ml |
Lipobase cream
Read all of this leaflet carefully because it contains important information for you.
This medicine is available without prescription. However, you still need to use Lipobase carefully to get the best results from it.
- Keep this leaflet. You may need to read it again.
- Ask your pharmacist if you need more information or advice.
- You must contact a doctor if your symptoms worsen or do not improve.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
- 1. What Lipobase is and what it is used for
- 2. Before you use Lipobase
- 3. How to use Lipobase
- 4. Possible side effects
- 5. How to store Lipobase
- 6. Further information
What Lipobase Is And What It Is Used For
Lipobase is an emollient cream which restores the physiological balance of the skin.
It enhances the hydration of the outer layer of the skin (epidermis), reduces dryness, prevents scaling and protects the skin from harm.
The cream is an oil-in-water emulsion with a high lipid content (70%). It does not contain perfume. The components of the cream are selected to minimise the risk of allergy.
Lipobase cream is indicated for the treatment of dry, sensitive and dehydrated skin. You may also use it against skin irritations caused by water or detergents and for maintaining improvement. You can use Lipobase cream alternately with creams or ointments containing corticosteroids. The cream may be used by adults and children.
Before You Use L
1. Name Of The Medicinal Product
Livial 2.5 mg tablets
2. Qualitative And Quantitative Composition
Each tablet contains 2.5 mg of tibolone.
For excipients, see 6.1.
3. Pharmaceutical Form
Tablet.
White, round and flat tablets with beveled edges and a diameter of 6 mm and coded “MK” above “2” on one side and “Organon*” on the other side.
4. Clinical Particulars
4.1 Therapeutic Indications
• Treatment of oestrogen deficiency symptoms in postmenopausal women, more than one year after menopause.
• Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.
For all women the decision to prescribe tibolone should be based on an assessment of the individual patient's overall risks and, particularly in the over 60s, should include consideration of the risk of stroke (see sections 4.4 and 4.8).
4.2 Posology And Method Of Administration
The dosage is one tablet per day. No dose adjustment is necessary for the elderly. The tablets should be swallowed with some water or other drink, preferably at the same time every day.
For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used.
A separate progestogen should not be added with Livial treatment.
Starting Livial
Women experiencing a natural menopause should commence treatment with Livial at least 12 months after their last natural bleed. In case of a surgical menopause, treatment with Livial may commence immedia
1. Name Of The Medicinal Product
Lercanidipine HCl 10 mg film-coated tablets
2. Qualitative And Quantitative Composition
One tablet contains 10 mg of lercanidipine hydrochloride, which is equivalent to 9.4 mg of lercanidipine.
For excipients, see 6.1.
3. Pharmaceutical Form
Film-coated tablet.
Yellow, circular, biconvex tablets, scored on one side.
4. Clinical Particulars
4.1 Therapeutic Indications
Lercanidpine HCl is indicated for the treatment of mild to moderate essential hypertension.
4.2 Posology And Method Of Administration
The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient's response.
Dose titration should be gradual, because it may take about 2 weeks before the maximal antihypertensive effect is apparent.
Some individuals, not adequately controlled on a single antihypertensive agent, may benefit from the addition of Lercanidipine to therapy with a beta-adrenoceptor blocking drug (atenolol), a diuretic (hydrochlorothiazide) or an angiotensin converting enzyme inhibitor (captopril or enalapril).
Since the dose-response curve is steep with a plateau at doses between 20-30 mg, it is unlikely that efficacy will be improved by higher doses; whereas side effects may increase.
Use in the elderly: although the pharmacokinetic data and clinical experience suggest that no adjustment of the daily dosage is required, special care should be exercised when initiating treatment in the elderly.
Use in children: since there is no clinical experience in patients unde
1. Name Of The Medicinal Product
Levetiracetam Actavis 750 mg film-coated tablets.
2. Qualitative And Quantitative Composition
Each film-coated tablet contains 750 mg levetiracetam.
Excipient: Each film-coated tablet contains 0.156 mg sunset yellow E110.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Film-coated tablet [tablet].
Oval, orange 19.0 x 9.3 mm marked with “L” on one side and “750” on the other side.
4. Clinical Particulars
4.1 Therapeutic Indications
Levetiracetam Actavis is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Levetiracetam Actavis is indicated as adjunctive therapy
• in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy.
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
4.2 Posology And Method Of Administration
Posology
Monotherapy for adults and adolescents from 16 years of age
The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1,5
1. Name Of The Medicinal Product
Lysodren 500 mg tablets
2. Qualitative And Quantitative Composition
Each tablet contains 500 mg of mitotane.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Tablet.
White, biconvex, round, scored tablets.
4. Clinical Particulars
4.1 Therapeutic Indications
Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma.
The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.
4.2 Posology And Method Of Administration
Treatment should be initiated and followed by a suitably experienced specialist.
Posology
Treatment in adults should be started with 2 - 3 g mitotane per day and increased progressively (e.g. at two
If it is urgent to control Cushing's symptoms in highly symptomatic patients, higher starting doses between 4 - 6 g daily could be necessary and daily dose increased more rapidly (e.g. every week). A starting dose higher than 6 g/day is generally not recommended.
Dose adjustments, monitoring and discontinuation
Dose adjustment is aimed to reach a therapeutic window (mitotane plasma levels between 14 and 20 mg/l) which ensures optimal use of Lysodren with acceptable safety. Indeed, neurologic toxicity has been associated with levels above 20 mg/l and therefore this threshold should not be reached. Weaker evidence has suggested that mitotane plasma levels above 14 mg/l may result in enhanced efficacy. Mitotane plasma levels higher than 20 mg/l may be associated with severe undesirable effects and offer no further benefit in terms
1. Name Of The Medicinal Product
LOCOID CREAM
2. Qualitative And Quantitative Composition
Contains 0.1% w/w hydrocortisone butyrate.
For excipients, see 6.1
3. Pharmaceutical Form
Cream
White to practically white cream.
4. Clinical Particulars
4.1 Therapeutic Indications
The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis.
Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided warnings are given, see section 4.4 Special warnings and special precautions for use.
4.2 Posology And Method Of Administration
For topical application.
Dosage: To be applied evenly and sparingly no more than twice daily.
Application may be made under occlusion in the more resistant lesions such as thickened psoriatic plaques on elbows and knees.
Adults and the Elderly: The same dose is used for adults and the elderly, as clinical evidence would indicate that no special dosage regimen is necessary in the elderly.
Children: Long term treatment should be avoided where possible.
Infants: Therapy should be limited if possible to a maximum of seven days.
4.3 Contraindications
Hypersensitivity to hydrocortisone or to any of the ingredients of the cream.
This preparation is contraindicated in the presence of untreated viral or fungal infections, tubercular or syphilitic lesions, peri-oral dermatitis, acne vulgaris and rosacea and in bacterial infections unless used in connection with appropriate chemotherapy.
1. Name Of The Medicinal Product
Lariam 250mg tablets
2. Qualitative And Quantitative Composition
Each tablet contains 250mg mefloquine (as 274.09mg mefloquine hydrochloride).
For excipients, see section 6.1.
3. Pharmaceutical Form
Tablet. White to off-white cylindrical biplanar tablets, cross scored and imprinted with Roche on one face.
4. Clinical Particulars
4.1 Therapeutic Indications
Therapy and prophylaxis of malaria.
Therapy: Lariam is especially indicated for therapy of P. falciparum malaria in which the pathogen has become resistant to other antimalarial agents.
Following treatment of P. vivax malaria with Lariam, relapse prophylaxis with an 8-amino-quinoline derivative, for example primaquine, should be considered in order to eliminate parasites in the hepatic phase.
Prophylaxis: Malaria prophylaxis with Lariam is particularly recommended for travellers to malarious areas in which multiple resistant P. falciparum strains occur.
For current advice on geographical resistance patterns and appropriate chemoprophylaxis, current guidelines or the Malaria Reference Laboratory should be consulted, details of which can be found in the British National Formulary (BNF).
4.2 Posology And Method Of Administration
Curative treatment
The recommended total therapeutic dose of mefloquine for non-immune patients is 20 – 25mg/kg. A lower total dose of 15mg/kg may suffice for partially immune individuals.
The recommended total therapeutic dosages of Lariam tablets relative to body weight and immune status are presented in the following table.*